Abstract: 5 0 AMP-activated protein kinase enzyme (AMPK), a master regulator of cellular metabolism, is recognized for its association with various metabolic diseases, inflammation and cancer. In this study, we aimed to investigate the role of compound 59, an AMPK activator, in a panel of oral squamous cell carcinoma (OSCC) cell lines. The antiproliferative effects of compound 59 were assessed by MTT assays, flow cytometry, Western blotting, confocal microscopy and transmission electron microscopy. Relative to OSCC cells, normal human oral keratinocytes were almost insensitive to compound 59 treatment. Compound 59 induced apoptosis as indicated by caspase activation and PARP cleavage. In addition, it inhibited JAK/STAT3 signalling, arrested cells in the G1 phase, increased reactive oxygen species (ROS) generation and promoted autophagy. Interestingly, pretreatment with a protein tyrosine phosphatase (PP2A) inhibitor, cantharidin, partially reversed compound 59-induced down-regulation of p-JAK2 and p-STAT3, thereby suggesting the involvement of a protein tyrosine phosphatase. Together, these findings substantiate the potential of compound 59 for the treatment of OSCC patients.
Oral squamous cell carcinoma (OSCC) remains a global health burden, causing substantial mortality and morbidity, particularly in the Asia-Pacific region [1] . Tobacco use, alcohol and betel quid chewing are among the major risk factors for the progression of OSCC. Surgery, radiation therapy, chemotherapy and targeted therapy represent the main treatment strategies for OSCC. However, in patients with recurrence, the survival rate is reduced by about 50% [2] , which highlights the urgent need to develop new approaches to manage this disease. 5 0 AMP-activated protein kinase enzyme (AMPK), a central metabolic sensor, regulates the cellular energy homeostasis when intracellular ATP levels change [3] . In response to its upstream kinase liver kinase (LKB1), AMPK is activated, leading to the modulation of many effectors that are involved in the pathogenesis and progression of cancer [4, 5] . Accumulating evidence indicated that AMPK activation correlated with a poor prognosis in lung, breast and liver cancers [6, 7] . Numerous reports demonstrated that AMPK activators prevent cancer cell growth via inhibition of mammalian target of rapamycin (mTOR), reduction of ERK activity, down-regulation of COX-2, and p53 activation in vitro and in vivo [8] [9] [10] . For example, metformin, an AMPK activator and a commonly used medicine for diabetic patients, was reported to block OSCC tumorigenesis via NF-jB and Aurora-A signalling inhibition in OSCC [11, 12] . Moreover, the in vitro activation of AMPK in OSCC with metformin could inhibit cell growth, induce apoptosis and chemosensitize cells to 5-fluorouracil [13] . The antitumour activity of compound 59 was previously reported against PTEN-null prostate cancer cells and its xenograft tumours in nude mice [14] . In this study, compound 59 0 s antitumour activity and the underlying mechanism against OSCC were investigated. Mechanistically, compound 59 was found to induce apoptosis, reactive oxygen species (ROS) generation and autophagy.
Materials and Methods
Reagents, antibodies and plasmids. Compound 59 was synthesized and characterized as described previously [14] . This compound and the other agents were dissolved in DMSO, diluted with culture medium and added to the cells at a final DMSO concentration of 0.1%. Cell culture. Oral squamous cell carcinoma cell lines, SCC4 and SCC2095, were kindly provided by Professor Susan R. Mallery (The Ohio State University) and cultured in DMEM/F12 (Gibco, Grand Island, NY, USA). Ca922 cells were purchased from the Japanese Cancer Research Resource Bank and cultured in MEM (Gibco). All culture medium for cancer cells were supplemented with 10% heatinactivated foetal bovine serum and penicillin (100 U/mL)/ streptomycin (100 lg/mL; Invitrogen, Carlsbad, CA, USA). Normal human oral keratinocytes (NHOKs) were kindly provided by Dr. Michael Yuanchien Chen (China Medical University) and maintained in keratinocyte serum-free medium (Gibco). All cells were cultured at 37°C in an atmosphere of 5% CO 2 .
Cell viability analysis. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in six replicates as described previously [15] . Briefly, 5 9 10 3 cells/well were seeded in 96-well flat-bottomed plates. Twenty-four hours later, cells were treated with DMSO or drug. After removing the medium, 200 lL medium containing 0.5 mg/mL of MTT was added, and cells were incubated in the CO 2 incubator at 37°C for 2 hr. Supernatants were aspirated from the wells, and the reduced MTT dye was solubilized in 200 lL/well DMSO. Absorbance at 570 nm was determined using a plate reader Synergy HT (Bio-Tek, Winooski, VT, USA).
Immunoblotting. Western blot analysis was performed as reported previously [16] . Briefly, treated cells were washed with phosphatebuffered saline (PBS), resuspended in SDS sample buffer, sonicated for 5 sec. and then boiled for 5 min. After centrifugation, equivalent amounts of proteins from the soluble fractions of cell lysates were resolved in 10% SDS-polyacrylamide gels on a Minigel apparatus and transferred to a nitrocellulose membrane using a semidry transfer cell. The transblotted membranes were washed thrice with TBS containing 0.05% Tween 20 (TBST). After blocking with TBST containing 5% non-fat milk for 120 min., the membranes were incubated with the appropriate primary antibodies at 1:500 dilution (with the exception of anti-b-actin antibody, 1:2000) in TBST-5% low-fat milk at 4°C overnight and then washed thrice with TBST. Membranes were probed with goat anti-rabbit or antimouse IgG-horseradish peroxidase conjugates (1:2500) for 90 min. at room temperature and washed thrice with TBST. The immunoblots were visualized by enhanced chemiluminescence.
Flow cytometry. Cells (2 9 10 5 /3 mL) were treated with DMSO or compound 59 at the indicated concentration for 24 hr. For cell cycle analysis, after being washed twice with ice-cold PBS, cells were fixed in 70% cold ethanol for 4 hr at 4°C, centrifuged at 1200 g for 5 min. and then resuspended in ice-cold PBS containing 2% FBS. Then, the cells were stained with propidium iodide (PI) and analysed using flow cytometry and the multicycler (ModFitLT 3.0) software program. For apoptosis evaluation, cells were stained with Annexin V and PI (1 lg/ mL) and counted using a BD FACSAria flow cytometer (Becton Dickinson, Becton, Germany). ROS production was detected using the fluorescence probe 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H2DCFDA, Molecular Probes, Eugene, OR, USA) according to the manufacturer's instruction. Briefly, cells were treated with DMSO or compound 59 with or without pre-treatment of glutathione (GSH) for 15 min. After 3 hr, the cells were washed with PBS twice and then stained with H2DCFDA (5 lM) at 37°C for 30 min. After washing with PBS, fluorescence intensity for ROS generation was assessed using a flow cytometer BD FACSAria (Becton Dickinson) with CellQuest software.
Transient transfection for confocal imaging. SCC2095 cells (2 9 10 5 /3 mL) were plated on cover slips in a six-well plate for 24 hr. Then, 1 lg GFP-LC3 plasmid was transiently transfected into SCC2095 cells using Fugene HD reagent (Roche, Mannheim, Germany) according to the manufacturer's protocol [16] . After 24-hr incubation, cells were treated with DMSO or compound 59 at the indicated concentrations or 30 lM rapamycin as the positive control for 1 hr and fixed in 2% paraformaldehyde for 30 min. at room temperature and permeabilized with 0.1% Triton X-100 for 20 min. Cells were washed with PBS and then covered before undergoing fluorescent microscopic examination.
Transmission electron microscopy. Cells were fixed in a solution containing 2% paraformaldehyde, 2.5% glutaraldehyde and 0.2 M sodium cacodylate for 1 hr. Then, the cells were suspended in a buffered solution containing 1% osmic acid for 1 hr, followed by dehydration in a graded ethanol series, washed with acetone and embedded into EPON epoxy resin. Ultrathin sections (60-80 nm) were stained with lead citrate combined with uranyl acetate and observed under a Hitachi H-600 transmission electron microscope (Hitachi, Tokyo, Japan).
Statistical analysis. All experiments were performed in three replicates. Statistical significance was determined with Student's t-test comparison between two groups of data sets. Differences between groups were considered significant at *p < 0.05, **p < 0.01.
Results
Compound 59 inhibits growth against oral cancer cells. SCC2095, SCC4 and Ca922 cell lines were first used to determine the antiproliferative effects of compound 59 using MTT assay. As shown in fig. 1A -C, compound 59 induced concentration-and time-dependent inhibition in these three OSCC cells. Notably, normal human oral keratinocytes (NHOKs) were almost insensitive to compound 59 ( fig. 1D ).
Compound 59 induces G1 arrest and apoptosis. To determine whether the reduced cell viability was attributed to the modulation of cell cycle, propidium iodide (PI) staining was performed. When compared to the control group, compound 59 at 2.5 lM concentration increased the cells in the G1 phase (from 47.7 AE 3.9% to 64.8 AE 1.8%) in SCC2095 cells. At 5 lM concentration, it increased those in sub-G1 phase (from 0.3 AE 0.2% to 27.7 AE 3.2%) after 24-hr treatment of SCC2095 cells (*p < 0.05). A similar phenomenon was also observed in compound 59-treated SCC4 oral cancer cells ( fig. 2A) . To further investigate the changes in the cell cycle-related proteins, total cell lysates from SCC2095 and SCC4 cells were collected for Western blotting. As shown in fig. 2B , compound 59 down-regulated the expression of cyclin A and cyclin B1, as well as cyclin D1 and CDK6 in a concentration-dependent manner in both SCC2095 and SCC4 cells.
Compound 59 induces apoptosis through caspase-dependent manner in oral cancer cells. Considering the increased percentage of cells at sub-G1 phase consequent to compound 59 treatment ( fig. 2A) , we further examined the apoptosis-related evidence. PI/Annexin V analysis demonstrated that the proportion of apoptotic cells were increased in a concentration-dependent manner after compound 59 treatment for 24 hr in both SCC2095 and SCC4 cells ( fig. 3A,B) . Increased apoptosis was further supported by PARP cleavage and increased cleavage of caspase-3 in compound 59-treated cells ( fig. 3C) . 
Compound 59 increases reactive oxygen species (ROS) generation.
A recent study by Gao et al., [17] demonstrated that the AMPK activator, metformin, disrupted normal mitochondrial function, leading to ROS production in breast cancer cells. Our study showed that compound 59 increased ROS generation in a concentration-dependent manner in both SCC2095 and SCC4 cells ( fig. 4A , H 2 O 2 as a positive control). Furthermore, pre-treatment with a ROS scavenger, glutathione (GSH), could partially oppose compound 59-induced ROS production ( fig. 4B ).
Compound 59 induces autophagic cell death. It has been reported that AMPK up-regulates autophagy, and autophagy degrades the dysfunctional subcellular organelles, consequently inhibiting cell survival or promoting cell death [18] . To determine whether the inhibition of cell growth was associated with autophagy, we evaluated some characteristic parameters of autophagy. Firstly, transmission electron microscopy (TEM) images demonstrated that compound 59 induced the accumulation of autophagosomes in SCC2095 cells ( fig. 5A ), a hallmark feature of autophagy. Secondly, SCC2095 cells were transiently transfected with GFP-tagged LC3 (GFP-LC3) plasmid and treated with compound 59 (2.5 or 5 lM) or 30 lM rapamycin (positive control). Confocal fluorescence imaging revealed that the accumulation of LC3-positive puncta in the cytoplasm was increased in a manner similar to that of rapamycin ( fig. 5B ). Thirdly, Western blot analysis indicated that the expression of LC3B-II and p62 was up-regulated after the compound 59 treatment in a concentration-dependent manner in SCC2095 and SCC4 cells ( fig. 5C ). In addition, compound 59 increased the expression of LC3B-II after 12-hr treatment in both SCC2095 and SCC4 cells ( fig. 5D ).
To further elucidate the role of autophagy in compound 59-induced cell death, we examined the combination effect of autophagic inhibitor chloroquine (CQ) and compound 59. As shown in fig 5E, PI/Annexin V analysis demonstrated that pre-treatment with CQ partially salvaged SCC2095 cells from compound 59-induced apoptotic death, whereas there was no rescue effect in SCC4 cells. Additionally, the expression of cleavage form of PARP and caspase-3 after the combination of CQ in SCC2095 and SCC4 cells supported the previous observation ( fig. 5F ).
Compound 59 inhibits JAK-STAT3 phosphorylation. Pyruvate kinase M2 (PKM2) is a predominant mediator of cancer aerobic glycolysis, and its overexpression has been observed in multiple human cancers including OSCC [19] . As shown in fig. 6A , phosphorylation of AMPK was up-regulated after compound 59 treatment in SCC2095 and SCC4 cells, while phosphorylation of PKM2 was down-regulated in [20] . Western blot analysis demonstrated that the phosphorylation of JAK2 and its downstream target activator of transcription-3 (STAT3) was down-regulated in compound 59-treated cells ( fig. 6A) . Furthermore, pre-treatment with the PP2A inhibitor cantharidin for 1 hr partially reversed the suppressive effect of compound 59 on the phosphorylation of JAK2 and STAT3 in SCC2095 and SCC4 cells ( fig. 6B ).
Discussion
Accumulating evidence disclosed a strong relation between metabolism disturbances and the occurrence of vascular diseases, diabetes mellitus and cancer [21, 22] [ 25, 26] . Moreover, Rodriguez et al. [27] showed that metformin inhibited leukaemia cell growth by inducing S and G2/M arrest through down-regulation of cyclin A and cyclin B1. Our results demonstrated that compound 59 induced G1 arrest at low concentration (2.5 lM), which was accompanied by the down-regulation of cell cycle-regulated proteins including cyclin A, cyclin B1, cyclin D1 and CDK6. The dissimilarity in the phase arrest between metformin and compound 59 might be attributed to the different cell types used or due to an AMPK-independent effect. For example, metformin induced G1 arrest through suppressing of E2F8 in an AMPK-independent manner in lung cancer cells [28] . In addition, compound 59 promoted caspase-dependent apoptosis in OSCC cells, which is consistent with AICAR, an AMPK activator, ability to trigger apoptosis in liver cells by activating caspase-3 [29] . Recent reports related autophagy to clinical cancer therapy failure, including chemotherapy and radiotherapy [30, 31] . For example, the extract of areca nut decreased cisplatin sensitivity in OSCC patients through the activation of autophagy [32] . Similarly, it has been reported that autophagy protected ovarian cancer cells against metformin-induced apoptosis. [33] . In contrary, compound 59 induced autophagosomes accumulation, and when an autophagic inhibitor CQ was used, compound 59-induced apoptosis, PARP cleavage and caspase-3 activation were all reduced, which suggested that compound 59 presumably induced autophagic cell death instead of autophagy in SCC2095 cells. Likewise, AMPK could promote OSCC stem cell survival through up-regulating PKM2 and subsequent autophagy and glycolysis [34, 35] . Our results demonstrated that compound 59 down-regulated the phosphorylation of AMPK and PKM2 in OSCC cells. As ROS generation constitutes one of the intracellular signal transducers that promote autophagy and the AMPK pathway, we found that the antioxidant glutathione partially rescued compound 59-induced ROS generation in both oral cancer cell lines. Furthermore, it has been reported that metformin could inhibit ROS production, as well as the oxidative stress in the heart of highfat-diet-treated rat and reduce mammary carcinogenesis [36] . It is possible that there are different additional mechanisms regulated by metformin and compound 59 and that further studies are needed.
Several studies correlated STAT3 increased phosphorylation with poorly differentiated OSCC tumour clinically and STAT3 signalling has been involved in OSCC oncogenesis [37, 38] . Kawashima et al. [20] demonstrated that metformin suppressed the growth of myeloproliferative neoplasm cells via inhibiting JAK2V617F activity, consequently activating AMPK and PP2A complex. Our results showed that compound 59 down-regulated the phosphorylation of JAK2 and STAT3 in OSCC cells, and this phenomenon could be partially reversed by the pre-treatment with a PP2A inhibitor, cantharidin ( fig. 6 ).
